BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its recurring company updates center on the CardiAMP autologous cell therapy platform, CardiALLO allogeneic cell therapy programs, and device and software technologies used to deliver therapies to the heart, including the Helix transendocardial delivery catheter and Heart3D Fusion Imaging software.
News about BCDA commonly covers clinical results in ischemic heart failure with reduced ejection fraction, FDA and Japan PMDA regulatory interactions, patent protection for procedure-planning and navigation technology, and annual financial results. Company communications also address the role of Helix and related vascular navigation platforms in minimally invasive intramyocardial delivery of therapeutic and diagnostic agents.
BioCardia (BCDA) will present the CardiAMP HF II trial design at the HFSA Annual Scientific Meeting on October 9–12, 2026.
The Phoenix presentation covers the design and scientific support for the ongoing multicenter, double-blind randomized controlled trial. It seeks to determine whether high-dose treatment using patients’ own cells is effective in ischemic heart failure with reduced ejection fraction, meaning reduced heart pumping capacity. Participants are receiving guideline-directed medical therapy but still have elevated biomarkers of heart stress.
FDA agreed the ongoing trial may be sufficient to support approval. FDA also approved a category B designation for the CardiAMP cell therapy system in three separate clinical trials. BioCardia said it is advancing the confirmatory trial alongside ongoing regulatory submissions to FDA and Japan’s PMDA.
BioCardia (BCDA) has completed a revised FDA De Novo pre-submission seeking clearance of its Helix catheter for delivery to the heart. The submission incorporates FDA advice on delivering therapeutic and diagnostic agents. At a May 2026 meeting, FDA agreed there were two pathways for marketing clearance and raised no concerns about safety data, device performance or compatibility with general classes of agents. FDA accepted the meeting minutes in August 2026.
The clinical experience includes 15 trials involving nearly 500 patients. This is a pre-submission, not marketing clearance. FDA targets an initial acceptance/refusal review within 15 calendar days and written feedback or a meeting within 70 calendar days. BioCardia sees potential for independent clearance to expand partnerships with developers of investigational cell, gene and protein therapeutics requiring targeted heart delivery.
BioCardia (BCDA) outlined upcoming regulatory milestones for its CardiAMP autologous cell therapy and Helix transendocardial delivery platform.
For CardiAMP in ischemic heart failure, the company is working toward a Shonin pre-market regulatory submission to Japan’s PMDA in Q4 2026, following detailed responses to PMDA consultation questions and preparation of the Shonin application, Quality Management System Application, and Foreign Manufacturer Registration. PMDA support and a successful review could lead to market clearance by Q4 2027.
The confirmatory CardiAMP HF II clinical study is actively enrolling at four centers in the United States, and FDA’s CBER has indicated this study may support a Pre Marketing Application. For the Helix catheter system, BioCardia plans to file a follow-on De Novo pre-submission with FDA’s CDRH this quarter, with FDA aiming for an initial acceptance/refusal review within 15 days and feedback or a meeting within 70 days.
BioCardia (BCDA) will present regulatory and corporate progress for its CardiAMP autologous cell therapy and related platforms at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 14-16, 2026.
The company is preparing a Shonin pre-market submission to Japan’s PMDA for CardiAMP for ischemic heart failure, targeted for the fourth quarter of 2026, following PMDA advice that a filing may be supported by three completed clinical trials with credible positive outcomes. In the United States, FDA meeting minutes received in June indicate that the ongoing randomized, double-blind CardiAMP HF II pivotal Phase III trial may support Premarket Approval for ischemic heart failure with reduced ejection fraction and is currently enrolling.
BioCardia is also advancing its Helix transendocardial delivery catheter toward a follow-on De Novo pre-submission to the FDA in the third quarter of 2026 and progressing its Heart3D fusion imaging platform toward a potential 510(k) submission, together positioning a targeted cardiac delivery and image-guided navigation platform for cell, gene and protein therapies.
BioCardia (Nasdaq: BCDA) reports that the FDA has confirmed and accepted the May 2026 Pre-Submission Meeting minutes for its Helix Transendocardial Delivery Catheter System, making them final and ratifying the company’s prior understanding of regulatory feedback.
BioCardia intends to submit a follow-on pre-submission for Helix this quarter incorporating FDA advice, which it believes could support a De Novo pathway approval. Helix is described as a minimally invasive catheter platform enabling targeted, intramyocardial delivery of therapeutic and diagnostic agents with precise placement and, according to BioCardia, superior retention compared with other delivery methods. The company also highlights upcoming catalysts across its CardiAMP and CardiALLO cell therapy programs, Helix delivery milestones, and its Heart3D fusion imaging platform through 2029.
BioCardia (Nasdaq: BCDA) reported second quarter 2026 results and regulatory progress for its cardiovascular cell therapies and enabling technologies.
Japan’s PMDA indicated support for a Shonin pre-market submission of CardiAMP Cell Therapy for ischemic heart failure based on three completed trials, while requesting additional data on guideline-directed medical therapy, revascularization eligibility and serious outcomes. The U.S. FDA informed BioCardia that the ongoing CardiAMP HF II trial may support a Premarket Approval filing. FDA also indicated De Novo approval of the Helix transendocardial delivery catheter is possible following a May pre-submission meeting.
In refractory angina, EuroPCR data showed the CardiAMP procedure was well-tolerated, with average exercise time improving 179 seconds and angina episodes reduced by 82% at six months, sustained to two years. Financially, Q2 operating cash use was $1.7 million; BioCardia raised $4.9 million via its ATM, ending with $4.1 million in cash and cash equivalents and reporting a narrower quarterly net loss of $1.6 million.
BioCardia (NASDAQ:BCDA) will host a conference call on Wednesday, August 12, 2026 at 4:30 PM EDT to provide a corporate update and report its Q2 2026 financial results. The event will include prepared remarks followed by a question-and-answer session.
Participants can register online to receive dial-in details or join by phone at 1-833-316-0559 (U.S.) or 1-412-317-5730 (international). A live webcast and both webcast and telephonic replays will be available, with webcast replay access through approximately November 12, 2026.
BioCardia (Nasdaq: BCDA) outlined 2026 priorities following a recent financing. The company is preparing a Shonin submission to Japan’s PMDA for CardiAMP cell therapy for ischemic heart failure, targeting an initial 20,000-patient subgroup within a 300,000-patient population, with precedent reimbursement of $124,000 per procedure.
Additional priorities include enrolling the U.S. CardiAMP HF II trial, advancing the Helix/Heart3D delivery platform, progressing allogeneic MSC programs with two FDA-cleared INDs, and pursuing partnerships. The financing is expected to fund the Japan submission, U.S. enrollment, and pipeline discussions.
BioCardia (Nasdaq: BCDA) completed a $4.4 million equity financing, selling 3,509,604 shares at an average price of $1.279 on June 5, 2026. Net proceeds are anticipated to extend the company’s cash runway into the first quarter of 2027, beyond the expected Japan PMDA submission. If currently outstanding warrants from prior financings are exercised for cash, BioCardia anticipates cash runway extending beyond PMDA approval and into initial commercial sales. No new warrants were issued in this capital raise.
BioCardia (Nasdaq: BCDA) reported that FDA minutes from a recent Q-Sub meeting indicate the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) of the CardiAMP Cell Therapy System for ischemic heart failure with reduced ejection fraction (HFrEF).
The FDA has previously indicated it typically prefers two well-designed trials for large indications like HFrEF and has already determined the system safe enough to enable Centers for Medicare and Medicaid reimbursement in CardiAMP HF trials.